Other Clinical Trial - Tislelizumab Monotherapy or Combined With

Updated 04/26/2024

Status Not yet recruiting

Clinical Trial Summary

This is a phase II prospective study to evaluate the safety and efficacy of Tislelizumab monotherapy or combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Hepatocellular
Resectable Hepatocellular Carcinoma

Clinical Trial Details

NCT number	NCT05807776
Study type	Interventional
Source	Tianjin Medical University Cancer Institute and Hospital
Contact	Tianqiang Song, Doctor
Phone	+8618622221077
Email	tjchi@hotmail.com
Status	Not yet recruiting
Phase	Phase 2
Start date	April 1, 2023
Completion date	December 31, 2025

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03222076` - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer	Phase 2
	Recruiting	`NCT04856046` - Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
	Completed	`NCT01522820` - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors	Phase 1
	Recruiting	`NCT04857684` - SBRT + Atezolizumab + Bevacizumab in Resectable HCC	Early Phase 1
	Recruiting	`NCT04701060` - Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma	Phase 2
	Not yet recruiting	`NCT05578430` - AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)	Phase 2
	Recruiting	`NCT02379377` - 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant	Phase 1
	Recruiting	`NCT04721132` - Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer	Phase 2
	Completed	`NCT06013657` - Surgical Resection for Hepatocellular Carcinoma
	Recruiting	`NCT05519410` - Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma	Phase 2
	Not yet recruiting	`NCT04834986` - Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma	Phase 2
	Recruiting	`NCT05701488` - SIRT With Tremelimumab and Durvalumab for Resectable HCC	Phase 1
	Withdrawn	`NCT04965714` - Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer	Phase 2